

# HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review)

XIAOXIA WANG, MEIJUAN CHEN, JING ZHOU and XU ZHANG

College of Basic Medicine, Nanjing University of Chinese Medicine, Nanjing 210046, P.R. China

Received December 26, 2013; Accepted February 27, 2014

DOI: 10.3892/ijo.2014.2399

**Abstract.** Among the heat shock proteins (HSP), HSP27, HSP70 and HSP90 are the most studied stress-inducible HSPs, and are induced in response to a wide variety of physiological and environmental insults, thus allowing cells to survive to lethal conditions based on their powerful cytoprotective functions. Different functions of HSPs have been described to explain their cytoprotective functions, including their most basic role as molecular chaperones, that is to regulate protein folding, transport, translocation and assembly, especially helping in the refolding of misfolded proteins, as well as their anti-apoptotic properties. In cancer cells, the expression and/or activity of the three HSPs is abnormally high, and is associated with increased tumorigenicity, metastatic potential of cancer cells and resistance to chemotherapy. Associating with key apoptotic factors, they are powerful anti-apoptotic proteins, having the capacity to block the cell death process at different levels. Altogether, the properties suggest that HSP27, HSP70 and HSP90 are appropriate targets for modulating cell death pathways. In this review, we summarize the role of HSP90, HSP70 and HSP27 in apoptosis and the emerging strategies that have been developed for cancer therapy based on the inhibition of the three HSPs.

## Contents

1. Introduction
2. Apoptosis
3. HSF1
4. Targeting HSP27
5. Targeting HSP70
6. Targeting HSP90
7. Conclusions

---

*Correspondence to:* Professor Xu Zhang, College of Basic Medicine, Nanjing University of Chinese Medicine, Nanjing 210046, P.R. China  
E-mail: zhangxutcm@gmail.com

*Key words:* heat shock proteins 27, 70 and 90, cancer, apoptosis

## 1. Introduction

Stress or heat shock proteins (HSPs) are a family of highly conserved proteins induced in response to a wide variety of physiological and environmental insults such as hypoxia, hyperoxia, exposure to UV light and chemicals, viral agents, surgical stress, nutritional deficiencies (e.g. glucose deprivation), emotional and mechanical stress, or other stresses, thus helping maintain cellular homeostasis under stress or allowing the cell to survive to lethal conditions (1-4).

Mammalian HSPs have been classified into six families according to their molecular size: HSP100, HSP90, HSP70, HSP60, HSP40 and small HSPs (15 to 30 kDa) including HSP27. Family members of HSPs are expressed either constitutively or regulated inductively, and are present in different subcellular compartments (5). High molecular weight HSPs are ATP-dependent chaperones, whereas small HSPs act in an ATP-independent fashion (5). As molecular chaperones, the function of HSPs is to regulate protein folding, transport, translocation and assembly, especially helping in the refolding of misfolded proteins or assisting in their elimination if they become irreversibly damaged after various stresses or environmental insults.

Cancer cells, with higher metabolic requirements and more abundant signal transduction pathways than normal cells, thereby have a higher need of chaperones than non-transformed cells to maintain cancer cells survival. In addition, by commanding over the folding and stabilization of relevant oncoproteins, HSPs stand at the crossroads of multiple important oncogenic pathways. Inhibition of HSPs hereby offers the unique advantage of depleting multiple oncoproteins while simultaneously attacking several pathways necessary for tumor progression (6). The most studied stress-inducible HSPs are HSP90, HSP70 and HSP27. Indeed, the expression and/or activity of the three HSPs is abnormally high in cancer cells and further increased after many different death stimuli (5,7). They are powerful anti-apoptotic proteins, associating with key apoptotic factors, and thereby blocking this cell death process at different levels (8). Preclinical trials have proved that overexpression of the HSPs increases tumor growth, metastatic potential, and resistance to chemotherapy in rodent models. The inhibition of HSP90, HSP70 and/or HSP27 is thus emerging as a novel strategy for cancer therapy. In this review, we will present our view on the role of HSP90, HSP70 and HSP27 in apoptosis (Fig. 1) and the emerging




Figure 1. HSP27, 70, 90 in the regulation of apoptosis and proliferation. HSP27, 70 and 90 regulate apoptosis at different levels, from the death receptors signaling to executors of cell death program, affecting both upstream and downstream of the death-associated mitochondrial events. Induction of caspase activation provokes proteasome activation. Also, HSPs facilitate the degradation of proteins by the ubiquitin/proteasome system (see text).

strategies that are being developed for cancer therapy in clinic based on the inhibition of these three HSPs.

## 2. Apoptosis

Mainly, two pathways of apoptosis can be distinguished, although crosstalk between the two signal transducing cascades is present: the intrinsic or mitochondrial pathway and the extrinsic or death receptors pathway. The two signal-transducing cascades meet at the point of caspase-3, an effector caspase that leads to the typical morphologic and biochemical changes of the apoptotic cell.

The intrinsic pathway involves intracellular stress signals that provoke the permeabilization of the outer mitochondrial membrane, resulting in the release of pro-apoptotic molecules normally confined to the intermembrane space. Outer mitochondrial membrane permeabilization leads to the release of caspase activators under control of the Bcl-2 (B-cell lymphocytic-leukaemia proto-oncogene) family of proteins. Bcl-2 proteins include anti-apoptotic members such as Bcl-2 and Bcl-xL, multi-domain pro-apoptotic members mainly Bax and Bak (9,10) and a series of BH3 domain-only pro-apoptotic proteins, such as Bid, that function upstream of Bax and Bak (11). One of the released mitochondrial molecules is cytochrome *c*, which interacts with cytosolic apoptosis protease-activating factor-1 (Apaf-1) and pro-caspase-9 to form

the caspase-3 activation complex, apoptosome (12). Apoptosis inducing factor (AIF) and the DNase, endonuclease G (EndoG), are other mitochondria intermembrane proteins released upon an apoptotic stimulus. They translocate to the nucleus and trigger caspase-independent nuclear changes (13). Two additional mitochondrial proteins, Smac/Diablo and Htra2/Omi, activate apoptosis by neutralizing the inhibitory activity of the IAPs (inhibitory apoptotic proteins) that associate with and inhibit some of the activated caspases (14).

The extrinsic pathway is triggered through plasma membrane proteins of the tumor necrosis factor (TNF) receptor family known as death receptors, and leads to the direct activation of caspases, starting with the receptor-proximal caspase-8 or caspase-10 in the death-inducing signalling complex (DISC). Caspase-8 either directly activates the downstream cascade of caspases or cleaves Bid into an active truncated form named tBid that connects the extrinsic to the intrinsic apoptotic pathways through mitochondria permeabilization (15).

## 3. HSF1

The rapid induction of HSPs in response to multiple stress is collectively referred to as the heat shock response (HSR)(16). The HSR is mediated at the transcriptional level by heat shock transcription factors (HSFs), the upstream transcriptional regulators of HSPs (17). So far, the vertebrates HSFs that have been




Figure 2. Heat shock factor 1 in the regulation of the expression of HSPs. HSP90 and HSP70 bind to HSF1 in unstressed state to abrogate the transcription function of HSF1 and dissociate from it under the exterior cellular stress to activate HSF1. Then the monomeric HSF1 trimerizes, phosphorylates and translocates to the nucleus. In the nucleus, HSF1 binds *cis*-acting DNA elements, termed heat shock elements (HSEs), which are present in heat shock genes, and activate transcription of the Hsp genes, e.g. HSP27, HSP70 and HSP90. HSF, heat shock factor; HSP, heat shock protein.

identified include HSF1, 2, 3, 4 and HSFY, all of which exhibit a similar structure with a highly conserved amino-terminal helix-turn-helix DNA-binding domain and a carboxy-terminal transactivation domain (18-20). Different HSFs are differently regulated and have a different impact on transcriptional responses, which suggests their specialized functions in response to distinct stimulation (21,22). Among them, HSF1 is considered as the master transcription factor for the HSR (17,23). It not only regulates the expression of HSPs but also orchestrates the survival of cells in response to different forms of cellular stress (21,23). In physiological conditions HSF1 exists as an inactive monomer. HSP90 and HSP70 can bind to HSF1 in unstressed state to abrogate the transcription function of HSF1 and dissociate from it under the exterior cellular stress to activate HSF1 (24). Then the monomeric HSF1 trimerizes, phosphorylates and translocates to the nucleus. In the nucleus, HSF1 binds *cis*-acting DNA elements, termed heat shock elements (HSEs), which are present in heat shock genes, and activate transcription of the Hsp genes, e.g. HSP27, HSP70 and HSP90 (6) (Fig. 2). The inhibition of HSP90 expression therefore should activate HSF1 with the increased expression of HSP27 and HSP70 (24). Because both HSP27 and HSP70 are anti-apoptotic proteins with tumorigenic properties, the overall anticancer effect of the HSP90 inhibitors might be impaired (see below). Considering this fact, targeting HSF1 should enable the simultaneous downregulation of several HSPs. Additionally, tumor cells are more dependent on HSF1 than normal cells for

proliferation and survival, as confirmed by both cell-based and clinically relevant examples (23). Consequently, the targeting of HSF1 can be considered as a potentially efficient strategy to combat cancer. However, lacking of specificity for HSF1 inhibitors simultaneously is its greatest deficiency.

#### 4. Targeting HSP27

**HSP27 structure.** HSP27 (HSPB1) belongs to a member of the small heat shock proteins (sHSP). The primary structure of HSP27 is highly homologous to other members of the sHSP family, containing the conserved  $\alpha$ -crystallin domain and differing in the C- and N-terminal regions. HSP27 is expressed in all human tissues, including astrocytes and primary neuronal cells but mainly in skeletal, smooth and cardiac muscles (25) and shares with other members of the small HSP family the capacity to be phosphorylated and oligomerize. Human Hsp27 can be phosphorylated on three serine residues 15, 78 and 82 and on threonine (Thr143) by a large number of kinases including MAPKAP kinases 2 and 3, p90Rsk, PKC, PKD and PKG (26). The phosphorylation is a reversible event that modulates the oligomerization of the protein: its dephosphorylation favors the formation of large oligomers (27,28). However, some studies have found that the ability to oligomerize is reduced in *in vitro* cell based assays by phosphorylation, and that *in vivo* oligomerization has been tied to cell-cell contact and is independent of phosphorylation

status (26,29). HSP27 can form oligomers of up to 1,000 kDa. This oligomerization is a highly dynamic process that seems to play a central role in regulating the chaperone activity of HSP27, the multimer being the binding competent state for affinity for client proteins (30). The dimer of HSP27 is the 'building block' for multimeric complexes. Particularly, phosphorylated and small oligomers of HSP27 are efficient in binding to F-actin and Daxx (31) and it is the phosphorylated form of HSP27 that protects from neurotoxicity (32).

*The function of HSP27 in cancer.* HSP27 has a strong protective effect on cells. High levels of HSP27 have been observed in many cancer types, and the tumorigenic potential of HSP27 has been observed in experimental models (33). Many clinical trials have also shown its association with promoting drug resistance, aggressive cancers, metastasis, and poor patient outcomes (34-37). The strong protective effect of HSP27 is mainly due to its vital function at apoptosis regulation. HSP27 is able to block apoptosis at different stages, because of its interaction with a number of partners implicated in the apoptotic pathways.

Numerous studies describe that HSP27 inactivates the caspase cascade through its binding with caspase-3 and cytochrome *c* released from mitochondria (38-40). Knockdown of HSP27 by small interfering RNAs displayed increased caspase-3 activation, thereby inducing more apoptosis (41). Other data also confirmed that HSP27 prevents apoptosis and induces resistance to chemotherapy through sequestration of cytochrome *c* when released from the mitochondria into the cytosol (38).

High intracellular levels of HSP27 can inhibit caspase activation by interfering upstream of the mitochondria (42). This effect seems to have connection with the ability of HSP27 to stabilize cytoskeletal elements including actin microfilaments, such as F-actin, to prevent the cytoskeletal disruption and Bid intracellular redistribution that precede cytochrome *c* release, which is also required for the activation of matrix metalloproteinase 2 (MMP2) (42). In myeloma cell lines, it has been reported that HSP27 activation blocks release of Smac (second mitochondria-derived activator of caspase) from mitochondria (43). In stressed cells, HSP27 has also shown its importance in Akt activation, through binding the protein kinase Akt (7). In renal epithelial cells, HSP27 indirectly inactivates Bax and its translocation to mitochondria. This is due to an increase of PI3-kinase activity that activates Akt and promotes interaction between Akt and Bax (38,44). The phosphorylated form of HSP27 directly interacts with death-domain-associated protein (Daxx), which connects Fas signaling to the protein kinase Ask1 that mediates caspase-independent cell death (7,31).

Large oligomers of HSP27 have also been described to display anti-oxidant property, which is related to its ability to maintain glutathione in its reduced (non-oxidized) form to abolish the production of the potentially lethal burst of intracellular reactive oxygen species (ROS) that can occur (45,46). These anti-oxidant properties of HSP27 particularly contribute to its cytoprotection in neuronal cells.

The function of HSP27 and the role that it plays in cancer were recently reviewed (38). These numerous reports account for the role of HSP27 in apoptotic cell death inhibition, which also emphasizes its properties in cancer therapy (44,47).

*The inhibition of HSP27 in cancer therapy.* The strong cytoprotective function of HSP27, together with the fact that this protein is overexpressed in most cancers, makes this chaperone an attractive target in cancer therapy. Depletion of HSP27 in various animal models induces the regression of tumors (48). Though starting late, Hsp27 therapies have produced only few advances after tremendous efforts.

The antisense oligonucleotide OGX-427 is the only known specific inhibitor of HSP27 that can be safely administered in patients and is currently in phase II clinical trials (<http://www.oncogenex.ca/>). OGX-427 targets the human hsp27 translation initiation site (5'-GGGACGCGGCGCTCGGTCAT-3') and prevents the translation of hsp27 mRNA, thereby decreasing the expression of the protein compared to untreated cells (49).

Less specific, the chemical molecule RP101 (also known as bromovinyldeoxyuridine, BVDU, brivudine) was reported to improve the efficacy of chemotherapy in pancreatic cancer through its interaction with HSP27 (50). RP101 is a nucleoside that binds via  $\pi$ -stacking with Phe29 and Phe33 of Hsp27 thereby inhibiting its function (50). Functioning as a chemosensitizing agent and preventing the development of resistance, RP101 recently completed a phase II clinical trial for the treatment of pancreatic cancer in combination with gemcitabine (Hidalgo M; <http://clinicaltrials.gov/ct2/show/NCT00550004?term=NCT00550004&rank=1>, 2011). However, overdosing caused an increase of the toxic side-effects of gemcitabine and thus the combination provided a 25% increase in survival only for patients that had a body surface area (BSA)  $\geq 1.85$  m<sup>2</sup> compared with gemcitabine combined with placebo (50). There were no side-effects caused by RP101, and more accurate dosing would likely improve the survival rates for all patients regardless of size (50). Development of second-generation candidates of RP101 are ongoing.

A strategy of peptide aptamers has also been used to target HSP27. Protein aptamers, small amino acid sequences, are designed to bind to a specific protein domain, thus inhibiting its function (51). Gibert *et al* have shown that peptide aptamers (PA11 and PA50) that specifically interact with HSP27 are able to disturb the dimerization and oligomerization of the chaperone, thereby acting as negative regulators of HSP27 anti-apoptotic and cytoprotective properties (52). PA11 prevents the HSP27 oligomerization, which leads to the inability of HSP27 to inhibit early stage protein aggregation and induces proteotoxic stress that ends in cell death. PA50, through a different mechanism, mainly inhibits HSP27 dimerization, disrupting the ability of HSP27 to participate in cell-signaling events thereby interfering with processes essential for cell survival. In xenograft models these peptide aptamers strongly reduced tumor cells growth (52). Similar to the small molecule inhibitors of HSP27, peptide aptamers are not effective on their own but are used to sensitize cancers to other therapies. The pre-clinical success of peptide aptamers suggests this avenue of cancer therapy has potential.

Different kind of inhibitors, which have been experimentally tested, like the flavonoid quercetin and the diterpene triepoxide, triptolide (24), act at the level of the HSF1 to block the transcription of heat shock proteins genes, thus inhibiting the heat shock response. However, such approaches are non-specific since through HSF1 inhibition, all the stress-inducible heat shock proteins can be blocked affecting important housekeeping functions in normal cells.

## 5. Targeting HSP70

*Human Hsp70: structure and general function.* HSP70 refers to a family of chaperone proteins that are 70 kDa. The HSP70 human genome superfamily consists of at least 13 members (53). There are four major proteins: constitutively expressed HSC70 (HSP73 or HSPA8), endoplasmic reticulum-localized GRP78/Bip, mitochondrial mtHSP70 and stress-inducible HSP70 (HSP72 or HSPA1) (called here simply HSP70) (54).

HSC70 is ubiquitously expressed in practically all organs and tissues. Under normal conditions, it functions as ATP-dependent molecular chaperone that assists the folding of newly synthesized polypeptides, the assembly of multi-protein complexes and the transport of proteins across cellular membranes (55-57). Its levels are also increased under stress conditions showing the involvement in stress response (57). On the contrary, the expression of HSP70 is often not observed under non-stress conditions. Under stressful conditions, elevated HSP70 levels allow cells to cope with increased concentrations of unfolded or denatured proteins (58).

All of the proteins share homology and contain two distinct functional domains: a C-terminal peptide-binding domain (PBD) and the N-terminal ATPase domain (ABD), which were connected through a hydrophobic linker and both domains are important for substrate binding and stabilization. The PBD, which include a carboxyl-terminal chaperone EEVD motif, is responsible for substrate binding and refolding. The ABD, containing the ATPase pocket and binding J-domain-containing proteins, such as HSP40 that regulate the HSP70 ATPase activity, in turn, facilitates the release of the client protein after ATP hydrolysis. A conserved proline in the ATPase domain is essential to alternate HSP70 conformations in response to ATP binding and hydrolysis (59,60).

HSP70 chaperone activity is regulated by distinct co-chaperones, e.g. Hip, CHIP or Bag-1. These co-chaperones bind to HSP70 and modulate its chaperone function by increasing or decreasing HSP70 affinity for substrates through the stabilization of the ADP or ATP bound state of HSP70. They can be classified into three groups. i) The J-domain co-chaperones, like HSP40, are a relatively large group that binds to the HSP70 ABD and stimulate the low ATPase activity of this chaperone (1). ii) The nucleotide exchange factor co-chaperones catalyze the release of ADP which is required for the completion of the HSP70 ATPase cycle. Members of this group are Bag-1, HSP110, or HSPBP1. iii) The TPR domain co-chaperones (Hop, CHIP) bind to the C-terminal EEVD motif presented in both HSP70 and HSP90. They are essential for combinational assembly of HSP70 and HSP90 complexes, required for the stabilization of HSP90 client proteins. CHIP, with ubiquitin ligase activity, has been implicated in the ubiquitination of at least some HSP client proteins (5,61).

*The function of HSP70 in cancer.* Similar to HSP27, HSP70 is also abundantly expressed in many tumor forms and is accompanied by increased cell proliferation, metastases and poor response to chemotherapy. Constitutively high expression of HSP70 enhances the ability of the cancer cells to survive to a range of lethal conditions. The cytotoxic effect of HSP70 down-modulation is particularly strong in transformed cells yet undetectable in normal, non-transformed cell lines or

primary cells (62). This fact has been interpreted by assuming that tumor cells, as compared to their normal counterparts, exhibit a constitutively stressed phenotype with an enhanced dependency on the cytoprotective action of HSP70. HSP70 exerts the cytoprotective action probably through its ability to inhibit apoptosis. Gene ablation studies demonstrate that HSP70 plays an important role in apoptosis. Cells lacking hsp70.1 and hsp70.3, the two genes that code for inducible HSP70, are highly sensitive to apoptosis induced by a wide range of lethal stimuli (62). Ablation of the testis specific isoform of HSP70 (hsp70.2) results in germ cell apoptosis (63).

HSP70 can regulate apoptosis at the different levels from death receptors signaling to executors of cell death program affecting both upstream and downstream of the death-associated mitochondrial events.

At the level of death receptors, HSP70 can bind to the death receptors DR4 and DR5, thereby inhibiting the TNF- $\alpha$ -related apoptosis-inducing ligand (TRAIL)-induced assembly and activity of death inducing signaling complex (DISC) (64). HSP70 also appears to affect the Bid-dependent apoptotic pathway. HSP70 inhibits TNF- $\alpha$ -induced cell death and this protective effect is lost in Bid homozygous-deleted MEF cells. HSP70 can block the cleavage of Bid by activated caspase-8 (65).

At the premitochondrial level, HSP70 inhibits stress-activated kinases, such as apoptosis signal regulating kinase 1 (Ask1). In NIH3T3 cells, it was shown that downregulation of HSP70 facilitates H<sub>2</sub>O<sub>2</sub>-induced Ask1 activation and subsequent apoptosis (66). HSP70 also negatively interferes with MAPK family kinase activity, in particular, the p38 kinase and the c-Jun N-terminal kinase (JNK) (67). Studies have found that HSP70 inhibits the apoptosis induced by hyperosmolarity modulating JNK and ERK phosphorylation (68). HSP70 has been shown to contribute to stabilize the stress-activated kinases, such as non-phosphorylated protein kinase C (PKC) and Akt, by means of binding to the non-phosphorylated kinase via the kinase unphosphorylated carboxyl-terminus, priming the kinase for rephosphorylation and stabilizing the protein (69).

HSP70 has also been shown to affect some transcription factors involved in the expression of the Bcl-2 family. Bcl-2 family of proteins, playing a critical role in the regulation of apoptosis through controlling the release of caspase activators, are transcriptional targets of the tumor suppressor protein p53. The transcription of Bcl-2 is repressed by p53, whereas that of Bax is induced. HSP70 can form stable complexes with mutated p53, thus inducing apoptosis in response to DNA damage. HSP70 can also cover the nuclear localization sequence of p53, thereby preventing its nuclear import (70).

At the mitochondrial level, HSP70 blocks heat-induced apoptosis by binding to Bax to prevent its translocation to the mitochondria (71), thus preventing outer mitochondrial membrane permeabilization and inhibiting the release of mitochondrial apoptogenic molecules, such as cytochrome *c* and AIF (72). This HSP70 function relies on both its chaperone HSP40, and its ATP hydrolytic domains.

At the post-mitochondrial level, downstream of the release of cytochrome *c* and upstream of the activation of caspase-3, HSP70 has been demonstrated to directly bind to Apaf-1 to prevent the recruitment of procaspase-9 to the apoptosome,

thus inhibiting apoptosis (73,74). This interaction depends on the ATPase domain of HSP70 (74).

HSP70 can prevent cell death under caspase inactivation. That is HSP70 can also prevent caspase-independent pathways (75,76). Indeed, HSP70 directly binds to AIF and inhibits AIF nuclear translocation, thereby inhibiting AIF-induced chromatin condensation (76-78). The ATPase function of HSP70 was described to be necessary for this interaction, which also depends on a region between amino acids 150 and 228 of AIF (76). HSP70 can also indirectly associate with EndoG to prevent DNA fragmentation through affecting AIF (79).

Moreover, HSP70 can also rescue cells from a later phase of apoptosis. During the final phases of apoptosis, the main characteristic is nuclear condensation and fragmentation, and the chromosomal DNA fragmentation is digested by the DNase CAD (caspase activated DNase) following activation by caspase-3. It has been reported that HSP70 has an important influence on the enzymatic activity and proper folding of CAD, which also depends on its cochaperones: HSP40 and the inhibitor of CAD(ICAD), suggesting that HSP70 plays a role in maintaining DNA integrity (80,81). Some studies also found that HSP70 could protect GATA-1, another final target of caspase-3, from caspase-3 cleavage (82). However, specific mechanism remains to be further studied.

HSP70 has been shown to promote cancer cell viability by safeguarding lysosomal integrity. In cysteine cathepsin-dependent death, HSP70 acts to inhibit lysosomal membrane permeabilization, thereby preventing the release of lysosomal constituents into the cytosol, which contains a group of proteases that are involved in apoptosis (83,84).

HSP70 is a crucial negative regulator of the mitochondrial pathway of apoptosis that can block cell death at several levels from death receptors signaling to executors of cell death program affecting both upstream and downstream of the death-associated mitochondrial events.

### *The inhibitors of HSP70*

Despite the critical role of HSP70, as discussed above, in protein regulation and cancer progression, tremendous efforts have produced few advances in hsp70 inhibitors. Here, we explore HSP70 inhibitors through three basic categories: small molecule inhibitors, protein aptamers, and antibody treatments, also, the targets of drugs - targeting PBD, targeting ABD and targeting HSP70 co-chaperones are also discussed.

*Small molecule inhibitors:* a) *Targeting the peptide binding domain (PBD).* A small molecule inhibitor called 2-phenylethanesulfonamide (PES) or pifithrin- $\mu$  interacts with the C-terminal PBD of HSP70, disrupting the association between HSP70 and several of its cofactors such as HSP40 and client proteins, including pro-apoptotic proteins: APAF-1, p53 and others (85). This disruption leads to the aggregation of misfolded proteins, and the destabilization of lysosome membranes, thus inducing cell death (85). PES has been proven as a potent antitumor agent.

Neutralization of HSP70 functions could be achieved with peptides that mimic a domain of the AIF which is required for HSP70 binding. The AIF-derived peptides were designed carrying the AIF region from amino acid 150 to 228, which was previously defined as required for HSP70 binding in its

PBD and lack AIF pro-apoptotic function (77). These peptides bind HSP70 and block its function (62,76). Experiments *in vitro* carried out on different cell lines, such as leukemia, colon and breast cancer lines, demonstrated that several of these peptides increase sensitivity to chemotherapy (62). Experiments *in vivo*: in syngeneic rat colon cancer and mouse melanoma models, demonstrated that AIF-derived decoy for HSP70 (ADD70), an inhibitor of HSP70, reduced the tumor size and metastatic potential, and led to a complete and permanent cure after treatment with cisplatin (86).

b) *Targeting the amino-terminal ATPase domain (ABD).* ATP hydrolysis and ADP/ATP exchange play a central role in HSP70 chaperone activity. Therefore, disruption of HSP70-ATP interaction could lead to the inability of HSP70 to perform its functions.

15-Deoxyspergualin (15-DSG), a natural immunosuppressive agent, disrupting HSP70-ATP interaction through binding to HSP70 and stimulating its ATPase activity, was the first compound described by Nadeau *et al* in 1994 (87). It binds ABD with its main structure, the dihydropyrimidine group. Screening for inhibitors of HSP70 ATPase activity and a subset of the National Cancer Institute drug collection brought about the identification of NSC630668, a dihydropyrimidine, which also effectively blocked protein translocation mediated by yeast HSC70 *in vitro* (88). Noteworthy is the second generation compound MAL3-101 and its subsequent modifications, which was described inhibiting HSP70 ATPase activity and blocking proliferation of SK-BR-3 cancer cells (89). Fortuitously, MAL2-11B, an intermediate in the synthesis of MAL3-101, was also shown to interfere with the activity of a viral J-domain of a chaperone-like protein, T antigen, suggesting that it may be a new class of polyomavirus inhibitors (90). However, the exact action mechanism of these molecules remains unclear.

VER-155008 is an adenosine-derived compound. It functions to inhibit the chaperone activity of HSP70 and other family members by binding the ATPase domain. Although further studies are necessary to determine its specificity and potency, some *in vitro* results are encouraging: inducing caspase-dependent apoptosis in BT474 breast cancer cells and non-caspase-dependent cell death in HCT116 colon cancer cells (91). This product has undergone pharmacokinetics studies in mice, but efficacy studies have yet to be reported.

Azure C, methylene blue and myricetin have been identified as inhibitors of HSP70 through a high-throughput screening for ATP turnover mediated by human HSP70, but their specificity for inducible HSP70 family has not yet been analyzed (92).

MKT-077, a cationic rhodacyanine dye analog, can also bind to the ABD of Hsp70 (93). Mechanistic studies indicate that MTK-077 localizes in the mitochondria where it inhibits the deleterious interaction of mitochondrial HSP70 with p53 by binding to the mt-HSP70 ABD (94). Studies on MKT-077 have generated significant excitement about this product and it has been explored on phase I clinical trial as an antitumor agent (95). However, MKT-077 was found to be nephrotoxic in solid tumor-bearing patients due to lack of binding specificity (95). Although the product does not specifically bind to HSP70 (i.e., it also binds to actin), such a drug-like compound deserves further investigation.

Apoptozole was discovered to induce apoptosis in the human embryonic carcinoma cell line while looking for small molecules that induced apoptosis in the imidazole compound library (96). It was shown to inhibit the ATPase activity of HSP70, but further information is required to define the precise molecular mode of action and the selectivity of this compound (97).

Sphingolipids, another group of HSP70 ABD binding agents, can bind and specifically inhibit HSP70 ATPase activity *in vitro* depending on the rate of ATP hydrolysis (98).

**Protein aptamers.** Peptide aptamers, targeting the ATP binding domain of HSP70 to attenuate the HSP70 function, were recently demonstrated as promising drugs in cancer therapy (51). The most potent aptamer, A17, binds to the ABD of HSP70 and disrupts the function of HSP70 in a biochemical assay *in vitro* (99). A17 increases the sensitivity to apoptosis induction by anticancer drugs (cisplatin and 5-fluorouracil) and, *in vivo*, has a strong antitumor effect (99).

**Antibody treatments.** The most promising strategy reported for developing HSP70 inhibitors utilizes the immune system, and it is the only HSP70-targeted therapy currently in clinical trials (clinicaltrials.gov). However, they are limited by the lack of tumor-specific markers (100). A recently developed monoclonal antibody, cmHsp70.1, successfully recognizes the extracellular motif, TKDNNLLGRFELSG (TKD) of membrane bound HSP70 (101). Furthermore, tumors express HSP70 in the membrane while normal (non-transformed) cells do not, thus making the TKD motif an excellent tumor-specific biomarker (101). CmHsp70.1 has successfully passed through a safety and efficacy phase I trial and it is currently in a phase II clinical trial for non-small cell lung cancer in combination with radio chemotherapy (102).

## 6. Targeting HSP90

**HSP90 structure.** HSP90, a highly abundant chaperone protein expressed by all eukaryotic cells, belongs to another important class of the HSP family (103). It is highly conserved throughout evolution and accounts for 1-2% of total cellular proteins, increasing upon induction from baseline levels to 4-6% (104). It is an ATP-dependent chaperone with various isoforms among which the most prominent members in humans are HSP90 $\alpha$  (inducible form) and HSP90 $\beta$  (constitutive form) isoforms (now also called HSPC1 and HSPC3, respectively) which are encoded by separate, but highly conserved genes, and have different roles (105). The hsp90 $\alpha$  was shown to be constitutively expressed at low level but strongly heat inducible. In contrast, the hsp90 $\beta$  gene (hsp90 $\alpha\beta$ 1) is expressed constitutively at a much higher level and is only weakly inducible following a heat shock (105). HSP90 exists as a homodimer and contains three major regions (104,106): i) the amino (N)-terminal domain, with an adenosine triphosphate (ATP)-binding and hydrolyzing pocket, is responsible for the protein's ATPase activity, ii) the charged middle linker region involved in co-chaperones and client proteins recognition/binding, and iii) the carboxy (C)-terminal dimerization domain which directs HSP90 dimerization contains the tetratricopeptide repeat-binding

(TRP) motif, EEVD. TPR-containing co-chaperones such as Hop (HSP organizing protein), bind to this motif regulating the ATPase function of HSP90 (17). ATP is required for HSP90 activity and it is possible to determine a potential conformational equilibrium of HSP90 (108,109). The available structural information for HSP90s shows that the C-terminal domains are involved in dimerization and that the dimer formation by these domains is independent of nucleotide binding or client proteins or co-chaperone interactions (108). On the other hand, the dimerization of the N-terminal domains is dependent on binding. The binding of ATP triggers the dimerization of the N-terminal domains and enables client protein binding/loading. HSP90-bound ATP is then hydrolyzed, and the energy released by ATP hydrolysis enables client protein folding (104). ATP hydrolysis results in a conformational changing from an elongated orientation in which the N-terminal domains dimerize to a wide, open V-shaped orientation releasing the client protein (108). There are a few contacts between the middle domains, a gap remains between the two middle domains, although each makes contact with the N-terminal domain of the other protomer upon dimerization of the N-termini (110).

**The function of HSP90 in cancer.** As a molecular chaperone, like HSP27 and HSP70, HSP90 helps nascent proteins adopt their biologically active conformations, correct the conformation of misfolded proteins, and helps incorrigibly misfolded proteins to be removed and degraded by the ubiquitin-proteasome system (104).

HSP90 functions as part of a multichaperone complex via association with a variety of co-chaperones and client proteins that rely on the complex for acquiring active conformation. It facilitates the maturation, stability, activity and intracellular sorting of more than 200 client proteins (104,111). These client proteins covering almost all cellular processes have been identified (for an updated list, see <http://www.picard.ch/downloads/Hsp90facts.pdf>). Many of these client proteins are involved in critical cellular functions that promote cell growth, proliferation and cell survival which are also important to maintain the cancer phenotype. HSP90 is overexpressed in cancer cells and several of its client proteins are signaling oncoproteins that represent nodal points in multiple oncogenic signaling pathways, including mutant cKIT, human epidermal growth factor receptor 2 (HER2)/neu, mutant epidermal growth factor receptor (EGFR), the BCR-ABL fusion protein and BRAF (111-113). HSP90 client proteins are also involved in other hallmark processes of cancer, including induction of angiogenesis, mediation of apoptosis, and promotion of tissue invasion and metastasis (114). For example, HSP90 influences angiogenesis by chaperoning hypoxia-inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) and vascular endothelial growth factor receptor (VEGFR) in addition to governing nitric oxide synthase upregulation. HSP90 chaperones client proteins that are apoptotic mediators, including Bcl-2, Apaf-1, the serine-threonine protein kinase AKT/PKB and surviving (114). Also, HSP90 may promote tissue invasion and metastasis through MMP-2 activation, digesting extracellular matrix proteins (114). Other client proteins of HSP90 that play a role in cell signaling processes include FAK (integrin pathway), IL6R (JAK/STAT3 pathway), I $\kappa$ B kinases (NF $\kappa$ B pathway), CDK 4,

6, 9, hTERT (cell cycle), p53 (tumor suppressor genes), and the steroid hormone receptors (estrogen receptor and androgen receptor) (115).

Because these oncogenic proteins substantially rely on the function of HSP90 for their maturation and/or stabilization, as well as regulation of their activated states (116), inhibition of HSP90 provides the unique advantage of causing depletion of multiple oncogenic client proteins, while simultaneously leading to blockade of many key cancer causing pathways, and hence leads to potent anticancer effect.

Over 20 co-chaperones regulate HSP90 activity mainly through the modulation between the interconversion of the ATP- and ADP-bound states. Some of these inhibit HSP90 ATPase activity, thus to be involved in client loading or the formation of mature HSP90 complexes, such as HSP70/HSP90 organizing protein (HOP), cell division cycle protein 37 (CDC37) and p23. Whereas, others enhance it, such as activator of HSP90 ATPase 1 (AHA1) and cyclophilin-40 (Cpr6 and Cpr7), hence leading to their use as activators of the HSP90 conformational cycle (104,117,118).

*Lessons learned in oncology clinical trials and future directions for oncology drug development of HSP90 inhibitors.* Many of HSP90 client proteins hold important functions in the development and promotion of cancer, as described above, thus, Hsp90 has a putative role in numerous cancers and deserves to be an attractive target for therapeutics. Targeting HSP90 as a therapeutic approach in treating cancer began with geldanamycin (GM), which exhibits antiproliferative activity by binding to the ATP-binding site of HSP90 and thereby preventing its function. However, GM has limited therapeutic potential owing to its hepatotoxicity. The discovery of GM sparked much interest in the inhibition of HSP90 as a strategy for the treatment of cancer, resulting in intense efforts from both industry and academic research institutes to develop clinically viable HSP90 inhibitors (119). Although the exact antitumor action of HSP90 inhibitors remains largely unknown, substantial number of molecules are currently in preclinical and clinical evaluations, and some have promising results. These inhibitors are summarized in Table I.

As illustrated above, the rationale for using HSP90 inhibitors in cancer therapy is well established. Pursuing after new easily administrable HSP90 inhibitors and their evaluation in clinical trials is a goal for many pharmaceutical companies. However, no HSP90 inhibitor has been FDA-approved to date. Lessons learned in oncology clinical trials give us strategies and future directions that may enhance therapeutic benefit and accelerate the drug approval process for safe and efficacious HSP90 inhibitors.

There have been hints that these inhibitors are minimally effective and with more side-effects as single agents against various cancer cell line, and that they may show tremendous promise when used as combination and dual treatment agents (120).

Inhibition of HSP90 activates the heat shock response, which compensatorily induces expression of several heat shock factors, including heat shock factor 1 (HSF1), members of the HSP70 family and HSP27, which are protective proteins that could counteract the pro-cell death effects of

HSP90 inhibitors (121). Therefore, an interesting approach for combination studies in the future is to inhibit multiple heat shock proteins. Silencing HSF1, HSP70 and HSP27, has been shown to cause a marked increase in the sensitivity of cancer cells to HSP90 inhibition, and induction of apoptosis (112). However, it should be noted that the toxicity of the combination of HSP70 and HSP90 inhibitors is unclear, and remains to be understood.

Since targeted therapy was introduced into cancer treatment, it has brought hope, and it is increasingly believed that combination therapies targeting parallel signaling pathways that regulate iconic processes that are absolutely necessary for cancer cell survival and proliferation may provide better cancer therapy. As described above, many of HSP90 client proteins are involved in critical cellular functions, thus, the development of these HSP90 inhibitors may require close developing client protein inhibitors, e.g., RAF inhibitors (114).

To enhance the effectiveness of HSP90 inhibitors, combinatorial targeting of HSP90 cochaperones and/or of post-translational modifications that influence HSP90's function is a potentially attractive approach (112). Then, a greater understanding of HSP90 cochaperones, and post-translational modifications of HSP90 is needed.

In addition, a better understanding of the HSP90 inhibitors is still the key. For HSP90 has various isoforms and each has different functions, specific inhibition for HSP90 inhibitors is expected. It has been suggested that HSP90 $\alpha$  plays an essential and unique role in embryo cell differentiation, and its inhibition blocks macrophagic differentiation in the already formed animal (122). Furthermore, only HSP90 $\alpha$  was described to emerge in the extracellular (breast cancer and melanoma) and to play a role in tumor invasion and metastasis by promoting maturation of extracellular MMP-2 (123). Evidences from that the concentration of secreted HSP90 $\alpha$  positively correlates with tumor malignancy in liver and breast tumor patients (124). Therefore, future drug discovery approaches should focus on looking for more specific inhibitors that only target the HSP90 $\alpha$  isoform. Similarly, drugs that specifically disrupt the interaction of HSP90 with a given chaperone or client protein without affecting others could be interesting to avoid the side-effects associated to HSP90 inhibitors (5).

Clinical trial designs may ultimately be critical in determining if one HSP90 inhibitor has any clear clinical benefit to exploit. Several strategies can be applied to enhance the effectiveness of HSP90 inhibitors. Personalizing treatments is always one of the principles of clinical treatment. Personalizing treatments to match patients' genetic profiles and targeting specific tumors/tumor types should be recognized as ways to increase the effectiveness of HSP90 inhibitors. As we enter the era of targeted therapy and personalised medicine, development of biomarkers to help to stratify patients, ascertain target inhibition, and monitor or predict response to HSP90 inhibitors is of vital importance if HSP90 inhibitors are to succeed. It is also possible that the therapeutic schedule of HSP90 inhibitors has not been optimized. Future effective target inhibition would benefit from a valuable method to optimise drug dosing and scheduling.



Table I. HSP inhibitors in clinical development as mono- or combination-therapy.

Drug (HSP90 inhibitors)	Disease type	Stage of development
<b>Geldanamycin analogues</b>		
Tanespimycin (17-AAG)		
17-AAG	Kidney tumors in Von Hippel-Lindau disease; relapsed or refractory anaplastic large cell lymphoma, mantle cell lymphoma, or Hodgkin's lymphoma	II
17-AAG + trastuzumab	Breast cancer	II
17-AAG + bortezomib	Multiple myeloma	II/III
17-AAG + gemcitabine	Recurrent advanced ovarian epithelial or peritoneal cavity cancer	II
17-AAG + bortezomib	Advanced solid tumors or lymphoma	I
<b>Alvespimycin (17-DMAG)</b>		
17-DMAG	Melanoma	I
	Prostate	I
17-DMAG + trastuzumab	Breast cancer	I
17-DMAG (KOS-1022) + trastuzumab	Ovarian	I
<b>Retaspimycin hydrochloride (IPI-504)</b>		
IPI-504	Hormone-resistant prostate cancer	II
	Relapsed and relapsed refractory multiple myeloma	I
	Relapsed/refractory stage IIIb, or stage IV NSCLC	I/II
IPI-504 + docetaxol	Advanced solid tumors	I
IPI-504 + everolimus	KRAS mutant NSCLC	I/II
IPI-504 + trastuzumab	HER2 <sup>+</sup> breast cancer (study terminated)	II
IPI-493	Advanced malignancies; hematologic malignancies (study terminated)	I
<b>Resorcinol derivatives</b>		
<b>Ganetespib (STA-9090)</b>		
STA-9090	Patients with unresectable stage III or stage IV melanoma who received prior tyrosine kinase inhibitor treatment (has 2 arms-mutant V600E BRAF arm and a wild-type BRAF arm); metastatic hormone-resistant prostate cancer previously treated with docetaxel-based chemotherapy; previously untreated metastatic HER2 <sup>+</sup> or triple negative breast cancer; stage IIIB/IV NSCLC; metastatic ocular melanoma; metastatic or unresectable GIST; refractory metastatic colorectal cancer	II
	Advanced hepatocellular carcinoma; solid tumors, STA-9090 administered twice-weekly	I
	AML, ALL and blast-phase CML	I/II
STA-9090 as second- or third-line therapy	Metastatic pancreatic cancer	II
STA-9090 + docetaxel	Solid tumors	I
STA-9090 + dutasteride	Castration-resistant prostate cancer	II
STA-9090 + fulvestrant	HR <sup>+</sup> , metastatic breast cancer	II
<b>AUY922</b>		
AUY922	Advanced solid malignancies in older patients (≥75 years)	I
	Lymphoma; metastatic pancreatic cancer resistant to first line chemotherapy; NSCLC patients who received 2 previous lines of chemotherapy; refractory GIST	II
	HER2 <sup>+</sup> trastuzumab-resistant breast cancer [imaging component using <sup>89</sup> Zr-trastuzumab positron emission tomography (PET) to study the effect of HSP90 inhibition on HER2 expression]	I/II
	ER <sup>+</sup> hormone therapy refractory breast cancer (to study the effect of HSP90 inhibition by AUY922 on VEGF using <sup>89</sup> Zr-bevacizumab PET)	I/II

Table I. Continued.

Drug (HSP90 inhibitors)	Disease type	Stage of development
AUY922 + capecitabine	Patients with advanced solid tumors (active not recruiting)	I
AUY922 + cetuximab	KRAS wild-type metastatic colorectal cancer	I
AUY922 + erlotinib hydrochloride	Stage IIIB/IV NSCLC	I/II
AUY922 + trastuzumab	Patients with HER2 <sup>+</sup> advanced gastric cancer, who had received trastuzumab plus chemotherapy as first line treatment	II
AT-13387	Refractory solid tumors	I
KW-2478		
KW-2478 + bortezomib	Relapsed or refractory multiple myeloma	I/II
Purine analogues		
BIIB021 (CNF 2024)		
BIIB021	Advanced solid tumors; advanced breast cancer (PK/PD study)	I
	GIST	II
BIIB021 + aromasin	Hormone receptor positive metastatic breast cancer	II
MPC-3100	Refractory or relapsed cancer	I
Debio 0932 (CUDC-305)	Advanced solid tumors or lymphoma	I
PU-H71	Refractory solid tumor and low-grade non-Hodgkin's lymphoma; advanced malignancies (metastatic solid tumor, lymphoma)	I
Other compounds		
SNX-5422	Refractory solid tumor malignancies or non-Hodgkin's lymphoma	I
DS-2248	Advanced solid tumors	I
XL-888		
XL-888	Solid tumors	I
XL-888 + AT13387, abiraterone	Prostate cancer	I
XL-888 + vemurafenib	Unresectable BRAF mutated stage III/IV melanoma	I

Source, ClinicalTrials.gov.

## 7. Conclusions

Owing to the complicated pathogenesis, poor prognosis and resistance to treatments, cancer remains a notoriously unsolved medical issue and desperately requires efficacious drug candidates. By commanding over the folding and stabilization of relevant oncoproteins, HSPs are involved in vital mechanisms of cancerous cells, such as cell proliferation, differentiation, invasiveness, neoangiogenesis, metastasis and immune system recognition. Additionally, they have the added advantage of reducing the likelihood of the tumor acquiring resistance to any single therapeutic strategy. As a consequence, HSPs are emerging as interesting targets in cancer therapy, particularly HSP90, 70 and 27. Owing to the potent anti-apoptotic function of HSPs 27, 70 and 90 as well as their role in drug resistance, it is considered that their deletion may increase tumor cell susceptibility to apoptosis and fight against carcinogenesis or elicit drug sensitivity (4). This is one area, which although representing a challenging endeavor with potential risks, offers very promising alternatives for the treatment of cancer. Several HSP inhibitors such as 17-AAG, IPI-504 and BIIB021 are currently in clinical phase trials. However, specificity is still an important issue for all the tested HSP inhibitors. HSP90 inhibitors repre-

sent the best developed candidates to treat cancer. However, as we reviewed above, these inhibitors targeting HSP90 are minimally effective and with more side-effects as single agents. Consequently, developing drug candidate targeting multiple HSPs or the combination of different HSP inhibitors could be particularly appealing. In addition, combining HSP inhibitors with other validated drug candidates for target therapies might provide promising therapeutic benefits. Although many issues remain unresolved, scientists in the field still continue to strive toward a better understanding of the mechanisms of HSPs/HSR and other essential oncogenic pathways, hoping that this will eventually lead to successful drug candidates and significantly improve cancer clinical therapeutic index.

## Acknowledgements

We acknowledge financial support from the National Science and Technology Research Supporting Programme in Chinese Medicine in '11th Five-Year Plan' (2006BAI11B08-01) and the Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) and thank for the assistance from Professor Xu Zhang of the Nanjing University of Medicine.

## References

- Young JC, Agashe VR, Siegers K and Hartl FU: Pathways of chaperone-mediated protein folding in the cytosol. *Nat Rev Mol Cell Biol* 5: 781-791, 2004.
- Lindquist S and Craig EA: The heat-shock proteins. *Annu Rev Genet* 22: 631-77, 1998.
- Lebret T, Watson RW and Fitzpatrick JM: Heat shock proteins: their role in urological tumours. *J Urolog* 169: 338-346, 2003.
- Khalil AA, Kabapy NF, Deraz SF and Smith C: Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? *Biochim Biophys Acta* 1816: 89-104, 2011.
- Jego G, Hazoumé A, Seigneuric R and Garrido C: Targeting heat shock proteins in cancer. *Cancer Lett* 332: 275-285, 2013.
- Xia Y, Rocchi P, Iovanna JL and Peng L: Targeting heat shock response pathways to treat pancreatic cancer. *Drug Discov Today* 17: 35-43, 2012.
- Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E and Kroemer G: Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. *Cell Cycle* 5: 2592-2601, 2006.
- Joly AL, Wettstein G, Mignot G, Ghiringhelli F and Garrido C: Dual role of heat-shock proteins as regulator of apoptosis and innate immunity. *J Innate Immun* 2: 238-247, 2010.
- Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. *Science* 292: 727-30, 2001.
- Zong WX, Lindsten T, Ross AJ, MacGregor GR and Thompson CB: BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. *Genes Dev* 15: 1481-1486, 2001.
- Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C and Kroemer G: Mechanisms of cytochrome c release from mitochondria. *Cell Death Differ* 13: 1423-1433, 2006.
- Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. *Cell* 91: 479-489, 1997.
- Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY, Sasaki T, Elia AJ, Cheng HY, Ravagnan L, Ferri KF, Zamzami N, Wakeham A, Hakem R, Yoshida H, Kong YY, Mak TW, Zuniga-Pflucker JC, Kroemer G and Penninger JM: Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. *Nature* 410: 549-554, 2001.
- Du C, Fang M, Li Y, Li L and Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. *Cell* 102: 33-42, 2000.
- Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. *Cell* 94: 481-490, 1998.
- Shamovsky I and Nudler E: New insights into the mechanism of heat shock response activation. *Cell Mol Life Sci* 65: 855-861, 2008.
- Akerfelt M, Morimoto RI and Sistonen L: Heat shock factors: integrators of cell stress, development and lifespan. *Nat Rev Mol Cell Biol* 11: 545-555, 2010.
- Green M, Schuetz TJ, Sullivan EK and Kingston RE: A heat-shock responsive domain of human HSF1 that regulates transcription activation domain function. *Mol Cell Biol* 15: 3354-3362, 1995.
- Sistonen L, Sarge KD and Morimoto RI: Human heat shock factors 1 and 2 are differentially activated and can synergistically induce hsp70 gene transcription. *Mol Cell Biol* 14: 2087-2099, 1994.
- Nakai A, Tanabe M, Kawazoe Y, Inazawa J, Morimoto RI and Nagata K: HSF4, a new member of the human heat shock factor family which lacks properties of a transcriptional activator. *Mol Cell Biol* 17: 469-481, 1997.
- Akerfelt M, Trouillet D, Mezger V and Sistonen L: Heat shock factors at a cross road between stress and development. *Ann NY Acad Sci* 1113: 15-27, 2007.
- Abane R and Mezger V: Roles of heat shock factors in gametogenesis and development. *FEBS J* 277: 4150-4172, 2010.
- Whitesell L and Lindquist S: Inhibiting the transcription factor HSF1 as an anticancer strategy. *Expert Opin Ther Targets* 13: 469-478, 2009.
- Westerheide SD, Kawahara TL, Orton K and Morimoto RI: Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. *J Biol Chem* 281: 9616-9622, 2006.
- Sugiyama Y, Suzuki A, Kishikawa M, Akutsu R, Hirose T and Wayne MM: Muscle develops a specific form of small heat shock protein complex composed of MKBP/HSPB2 and HSPB3 during myogenic differentiation. *J Biol Chem* 275: 1095-1104, 2000.
- Kostenko S and Moens U: Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. *Cell Mol Life Sci* 66: 3289-3307, 2009.
- Shin KD, Lee MY, Shin DS, Lee S, Son KH, Koh S, Paik YK, Kwon BM and Han DC: Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KR1BB3, a synthetic molecule that inhibits Hsp27 phosphorylation. *J Biol Chem* 280: 41439-41448, 2005.
- Gobbo J, Gaucher-Di-Stasio C, Weidmann S, Guzzo J and Garrido C: Quantification of HSP27 and HSP70 molecular chaperone activities. *Methods Mol Biol* 787: 137-143, 2011.
- Bruey JM, Paul C, Fromentin A, Hilpert S, Arrigo AP, Solary E and Garrido C: Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. *Oncogene* 19: 4855-4863, 2000.
- Shashidharamurthy R, Koteiche HA, Dong J and McHaourab HS: Mechanism of chaperone function in small heat shock proteins: Dissociation of the HSP27 oligomer is required for recognition and binding of destabilized T4 lysozyme. *J Biol Chem* 280: 5281-5289, 2005.
- Charette SJ, Lavoie JN, Lambert H and Landry J: Inhibition of Daxx-mediated apoptosis by heat shock protein 27. *Mol Cell Biol* 20: 7602-7612, 2000.
- Akbar MT, Lundberg AM, Liu K, Vidyadaran S, Wells KE, Dolatshad H, Wynn S, Wells DJ, Latchman DS and de Belleruche J: The neuroprotective effects of heat shock protein 27 overexpression in transgenic animals against kainate-induced seizures and hippocampal cell death. *J Biol Chem* 278: 19956-19965, 2003.
- Straume O, Shimamura T, Lampa MJ, Carretero J, Øyan AM, Jia D, Borgman CL and Southeray M: Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. *Proc Natl Acad Sci USA* 109: 8699-8704, 2012.
- Bauer K, Nitsche U, Slotta-Huspenina J and Drecoll E, Von Weyhern CH, Rosenberg R, Höfler H and Langer R: High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer. *Cell Oncol (Dordr)* 35: 197-205, 2012.
- Chen SF, Nieh S, Jao SW, Liu CL, Wu CH, Chang YC, Yang CY and Lin YS: Quercetin suppresses drug-resistant spheres via the p38 MAPK-Hsp27 apoptotic pathway in oral cancer cells. *PLoS One* 7: e49275, 2012.
- Ciocca DR, Arrigo AP and Calderwood SK: Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update. *Arch Toxicol* 87: 19-48, 2013.
- Pavan S, Musiani D, Torchiario E, Migliardi G, Gai M, Di Cunto F, Erriquez J, Olivero M and Di Renzo MF: HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor. *Int J Cancer* 134: 1289-1299, 2013.
- Acunzo J, Katsogiannou M and Rocchi P: Small heat shock proteins HSP27 (HspB1),  $\alpha$ B-crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. *Int J Biochem Cell Biol* 44: 1622-1631, 2012.
- Schmitt E, Gehrmann M, Brunet M, Multhoff G and Garrido C: Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. *J Leukoc Biol* 81: 15-27, 2007.
- Voss OH, Batra S, Kolattukudy SJ, Gonzalez-Mejia ME, Smith JB and Doseff AI: Binding of caspase-3 prodomain to heat shock protein 27 regulates monocyte apoptosis by inhibiting caspase-3 proteolytic activation. *J Biol Chem* 282: 25088-25099, 2007.
- Rocchi P, Jugpal P, So A, Sinneman S, Ettinger S, Fazli L, Nelson C and Gleave M: Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. *BJU Int* 98: 1082-1089, 2006.
- Paul C, Manero F, Gonin S, Kretz-Remy C, Viroit S and Arrigo AP: Hsp27 as a negative regulator of cytochrome c release. *Mol Cell Biol* 22: 816-834, 2002.

43. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Catley L, Tai YT, Hayashi T, Shringarpure R, Burger R, Munshi N, Ohtake Y, Saxena S and Anderson KC: Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. *Blood* 102: 3379-3386, 2003.
44. Havasi A, Li Z, Wang Z, Martin JL, Botla V and Ruchalski K: Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism. *J Biol Chem* 283: 12305-12313, 2008.
45. Arrigo AP, Viot S, Chaufour S, Firdaus W, Kretz-Remy C and Diaz-Latoud C: Hsp27 consolidates intracellular redox homeostasis by upholding glutathione in its reduced form and by decreasing iron intracellular levels. *Antioxid Redox Signal* 7: 414-422, 2005.
46. Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse C, Paul C, Wieske M, Arrigo AP, Buchner J and Gaestel M: Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. *J Biol Chem* 274: 18947-18956, 1999.
47. Sanchez-Niño MD, Sanz AB, Sanchez-Lopez E, Ruiz-Ortega M, Benito-Martin A, Saleem MA, Mathieson PW, Mezzano S, Egido J and Ortiz A: HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by highglucose and angiotensin II. *Lab Invest* 92: 32-45, 2012.
48. Solary E, Droin N, Bettaieb A, Corcos L, Dimanche-Boitrel MT and Garrido C: Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. *Leukemia* 14: 1833-1849, 2000.
49. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E and Gleave M: Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. *Mol Cancer Ther* 6: 299-308, 2007.
50. Heinrich JC, Tuukkanen A, Schroeder M, Fahrigh T and Fahrigh R: RP101 (briuvidine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. *J Cancer Res Clin Oncol* 137: 1349-1361, 2011.
51. Seigneuric R, Gobbo J, Colas P and Garrido C: Targeting cancer with peptide aptamers. *Oncotarget* 2: 557-561, 2011.
52. Gibert B, Hadchity E, Czekalla A, Aloy MT, Colas P, Rodriguez-Lafrasse C, Arrigo AP and Diaz-Latoud C: Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers. *Oncogene* 30: 3672-81, 2011.
53. Kampinga HH, Hageman J, Vos MJ, Kubota H, Tanguay RM, Bruford EA, Cheetham ME, Chen B and Hightower LE: Hightower. Guidelines for the nomenclature of the human heat shock proteins. *Cell Stress Chaperones* 14: 105-111, 2009.
54. Jäättelä M: Heat shock proteins as cellular lifeguards. *Ann Med* 31: 261-271, 1999.
55. Beckmann RP, Mizzen LE and Welch WJ: Interaction of Hsp 70 with newly synthesized proteins: Implications for protein folding and assembly. *Science* 248: 850-854, 1990.
56. Murakami H, Pain D and Blobel G: 70-kD heat shock-related protein is one of at least two distinct cytosolic factors stimulating protein import into mitochondria. *J Cell Biol* 107: 2051-2057, 1988.
57. Shi Y and Thomas JO: The transport of proteins into the nucleus requires the 70-kilodalton heat shock protein or its cytosolic cognate. *Mol Cell Biol* 12: 2186-2192, 1992.
58. Nollen EA, Brunsting JF, Roelofs H, Weber LA and Kampinga HH: In vivo chaperone activity of heat shock protein 70 and thermotolerance. *Mol Cell Biol* 19: 2069-2079, 1999.
59. Vogel M, Bukau B and Mayer MP: Allosteric regulation of Hsp70 chaperones by a proline switch. *Mol Cell* 21: 359-367, 2006.
60. Goloudina AR, Demidov ON and Garrido C: Inhibition of HSP70: a challenging anti-cancer strategy. *Cancer Lett* 325: 117-124, 2012.
61. Bukau B, Weissman J and Horwich A: Molecular chaperones and protein quality control. *Cell* 125: 443-451, 2006.
62. Schmitt E, Parcellier A, Gurbuxani S, Cande C, Hammann A, Morales MC, Hunt CR, Dix DJ, Kroemer RT, Giordanetto F, Jäättelä M, Penninger JM, Pance A, Kroemer G and Garrido C: Chemosensitization by a non-apoptogenic heat-shock protein 70-binding apoptosis-inducing factor mutant. *Cancer Res* 63: 8233-8240, 2003.
63. Dix DJ, Allen JW, Collins BW, Mori C, Nakamura N, Poorman-Allen P, Goulding EH and Eddy EM: Targeted gene disruption of Hsp70-2 results in failed meiosis, germ cell apoptosis, and male infertility. *Proc Natl Acad Sci USA* 93: 3264-3268, 1996.
64. Johnson TR, Stone K and Nikrad M: The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. *Oncogene* 22: 4953-4963, 2003.
65. Hui-qing X, Jian-da Z, Xin-min N, Yan-zhong Z, Cheng-qun L, Quan-yong H, Yi X, Pokharel PB, Shao-hua W and Dan X: HSP70 inhibits burn serum-induced apoptosis of cardiomyocytes via mitochondrial and membrane death receptor pathways. *J Burn Care Res* 29: 512-518, 2008.
66. Park HS, Cho SG, Kim CK, Hwang HS, Noh KT, Kim MS, Huh SH, Kim MJ, Ryoo K, Kim EK, Kang WJ, Lee JS, Seo JS, Ko YG, Kim S and Choi EJ: Heat shock protein hsp72 is a negative regulator of apoptosis signal-regulating kinase 1. *Mol Cell Biol* 22: 7721-7730, 2002.
67. Park HS, Lee JS, Huh SH, Seo JS and Choi EJ: Hsp72 functions as a natural inhibitory protein of c-Jun N-terminal kinase. *EMBO J* 20: 446-456, 2001.
68. Lee JS, Lee JJ and Seo JS: HSP70 deficiency results in activation of c-Jun N-terminal kinase, extracellular signal-regulated kinase, and caspase-3 in hyperosmolarity-induced apoptosis. *J Biol Chem* 280: 6634-6641, 2005.
69. Gao T and Newton AC: The turn motif is a phosphorylation switch that regulates the binding of Hsp70 to protein kinase C. *J Biol Chem* 277: 31585-31592, 2002.
70. Zyllicz M, King FW and Wawrzynow A: Hsp70 interactions with the p53 tumour suppressor protein. *EMBO J* 20: 4634-4638, 2001.
71. Yang X, Wang J, Zhou Y, Wang Y, Wang S and Zhang W: Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovariancancer cells. *Cancer Lett* 321: 137-143, 2012.
72. Stankiewicz AR, Lachapelle G, Foo CP, Radicioni SM and Mosser DD: Hsp70 inhibits heat-induced apoptosis upstream of mitochondria by preventing Bax translocation. *J Biol Chem* 280: 38729-38739, 2005.
73. Li CY, Lee JS, Ko YG, Kim JI and Seo JS: Heat shock protein 70 inhibits apoptosis down-stream of cytochrome c release and upstream of caspase-3 activation. *J Biol Chem* 275: 25665-25671, 2000.
74. Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Taitor P, Morimoto RI, Cohen GM and Green DR: Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. *Nat Cell Biol* 2: 469-475, 2000.
75. Creagh EM, Carmody RJ and Cotter TG: Heat shock protein 70 inhibits caspase-dependent and-independent apoptosis in Jurkat T cells. *Exp Cell Res* 257: 58-66, 2000.
76. Ravagnan L, Gurbuxani S, Susin SA, Maise C, Daugas E, Zamzani N, Mak T, Jaattela M, Penninger JM, Garrido C and Kroemer G: Heat-shock protein 70 antagonizes apoptosis-inducing factor. *Nat Cell Biol* 3: 839-843, 2001.
77. Gurbuxani S, Schmitt E, Cande C, Parcellier A, Hammann A, Daugas E, Kouranti I, Spahr C, Pance A, Kroemer G and Garrido C: Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor. *Oncogene* 22: 6669-6678, 2003.
78. Matsumori Y, Hong SM, Aoyama K, Fan Y, Kayama T, Sheldon RA, Vexler ZS, Ferriero DM, Weinstein PR and Liu J: Hsp70 overexpression sequesters AIF and reduces neonatal hypoxic/ischemic brain injury. *J Cereb Blood Flow Metab* 25: 899-910, 2005.
79. Kalinowska M, Garnarcz W, Pietrowska M, Garrard WT and Widlak P: Regulation of the human apoptotic DNase/RNase endonuclease G: Involvement of Hsp70 and ATP. *Apoptosis* 10: 821-830, 2005.
80. Sakahira H and Nagata S: Cotranslational folding of caspase-activated DNase with Hsp70, Hsp40, and inhibitor of caspase-activated DNase. *J Biol Chem* 277: 3364-3370, 2002.
81. Liu QL, Kishi H, Ohtsuka K and Muraguchi A: Heat shock protein 70 binds caspase-activated DNase and enhances its activity in TCR-stimulated T cells. *Blood* 102: 1788-1796, 2003.
82. Ribeil JA, Zermati Y, Vandekerckhove J, Cathelin S, Kersual J, Dussiot M, Coulon S, Moura IC, Zeuner A, Kirkegaard-Sørensen T, Varet B, Solary E, Garrido C and Hermine O: Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. *Nature* 445: 102-105, 2007.
83. Gyrð-Hansen M, Nylandsted J and Jaattela M: Heat shock protein 70 promotes cancer cell viability by safeguarding lysosomal integrity. *Cell Cycle* 3: 1484-1485, 2004.

84. Nylandsted J, Gyrd-Hansen M, Danielewicz A, Fehrenbacher N, Lademann U, Hoyer-Hansen M, Weber E, Multhoff G, Rohde M and Jaattela M: Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. *J Exp Med* 200; 425-435, 2004.
85. Leu JI, Pimkina J, Frank A, Murphy ME and George DL: A small molecule inhibitor of inducible heat shock protein 70. *Mol Cell* 36: 15-27, 2009.
86. Schmitt E, Maingret L, Puig PE, Rerole AL, Ghiringhelli F, Hammann A, Solary E, Kroemer G and Garrido C: Heat-shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. *Cancer Res* 66: 4191-4197, 2006.
87. Nadeau K, Nadler SG, Saulnier M, Tepper MA and Walsh CT: Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. *Biochemistry* 33: 2561-2567, 1994.
88. Fewell SW, Day BW and Brodsky JL: Identification of an inhibitor of hsc70-mediated protein translocation and ATP hydrolysis. *J Biol Chem* 276: 910-914, 2001.
89. Rodina A, Vilenchik M, Moullick K, Aguirre J, Kim J, Chiang A, Litz J, Clement CC, Kang Y, She Y, Wu N, Felts S, Wipf P, Massague J, Jiang X, Brodsky JL, Krystal GW and Chiosis G: Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. *Nat Chem Biol* 3: 498-507, 2007.
90. Wright CM, Seguin SP, Fewell SW, Zhang H, Ishwad C, Vats A, Lingwood CA, Wipf P, Fanning E, Pipas JM and Brodsky JL: Inhibition of SimianVirus 40 replication by targeting the molecular chaperone function and ATPase activity of T antigen. *Virus Res* 141: 71-80, 2009.
91. Massey AJ, Williamson DS, Browne H, Murray JB, Dokurno P, Shaw T, Macias AT, Daniels Z, Geoffroy S, Dopson M, Lavan P, Matassova N, Francis GL, Graham CJ, Parsons R, Wang Y, Padfield A, Comer M, Drysdale MJ and Wood M: A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. *Cancer Chemother Pharmacol* 66: 535-545, 2010.
92. Jinwal UK, Miyata Y, Koren J III, Jones JR, Trotter JH, Chang L, O'Leary J, Morgan D, Lee DC, Shults CL, Rousaki A, Weeber EJ, Zuiderweg ER, Gestwicki JE and Dickey CA: Chemical manipulation of hsp70 ATPase activity regulates tau stability. *J Neurosci* 29: 12079-88, 2009.
93. Wadhwa R, Sugihara T, Yoshida A, Nomura H, Reddel RR, Simpson R, Maruta H and Kaul SC: Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. *Cancer Res* 60: 6818-6821, 2000.
94. Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y, Reddel RR and Kaul SC: Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. *Exp Cell Res* 274: 246-253, 2002.
95. Britten CD, Rowinsky EK, Baker SD, Weiss GR, Smith L, Stephenson J, Rothenberg M, Smetzer L, Cramer J, Collins W, Von Hoff DD and Eckhardt SG: A phase I and pharmacokinetic study of the mitochondrial-specific rhodocyanine dye analog MKT 077. *Clin Cancer Res* 6: 42-49, 2000.
96. Williams DR, Ko SK, Park S, Lee MR and Shin I: An apoptosis-inducing small molecule that binds to heat shock protein 70. *Angew Chem Int Ed Engl* 47: 7466-7469, 2008.
97. Powers MV, Jones K, Barillari C, Westwood I, van Montfort RL and Workman P: Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? *Cell Cycle* 9: 1542-1550, 2010.
98. Whetstone H and Lingwood C: 3'Sulfogalactolipid binding specifically inhibits Hsp70 ATPase activity in vitro. *Biochemistry* 42: 1611-1617, 2003.
99. Chatterjee M, Andrus M, Stühmer T, Müller E, Hofmann C, Steinbrunn T, Heimberger T, Schraud H, Kressmann S, Einsele H and Bargou RC: The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. *Haematologica* 98: 1132-1141, 2013.
100. Multhoff G and Radons J: Radiation, inflammation, and immune responses in cancer. *Front Oncol* 2: 58, 2012.
101. Stangl S, Gehrman M, Riegger J, Kuhs K, Riederer I, Sievert W, Hüb K, Mociak R, Dressel R, Kremmer E, Pockley AG, Friedrich L, Vigh L, Skerra A and Multhoff G: Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. *Proc Natl Acad Sci USA* 108: 733-738, 2011.
102. Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K and Multhoff G: Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. *Clin Cancer Res* 10: 3699-3707, 2004.
103. Whitesell L and Lindquist SL: HSP90 and the chaperoning of cancer. *Nat Rev Cancer* 5: 761-772, 2005.
104. Taipale M, Jarosz DF and Lindquist S: HSP90 at the hub of protein homeostasis: emerging mechanistic insights. *Nat Rev Mol Cell Biol* 11: 515-528, 2010.
105. Sreedhar AS, Kalmár E, Csermely P and Shen YF: Hsp90 isoforms: functions, expression and clinical importance. *FEBS Lett* 562: 11-15, 2004.
106. Hartl FU, Bracher A and Hayer-Hartl M: Molecular chaperones in protein folding and proteostasis. *Nature* 475: 324-332, 2011.
107. Onuoha SC, Coulstock ET, Grossmann JG and Jackson SE: Structural studies on the co-chaperone Hop and its complexes with Hsp90. *J Mol Biol* 379: 732-744, 2008.
108. Mayer MP: Gymnastics of molecular chaperones. *Mol Cell* 39: 321-331, 2010.
109. Kruenberg KA, Street TO, Lavery LA and Agard DA: Conformational dynamics of the molecular chaperone Hsp90. *Q Rev Biophys* 44: 229-255, 2011.
110. Ali MM, Roe SM, Vaughan CK, Meyer P, Panaretou B and Piper PW: Crystalline structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. *Nature* 440: 1013-1017, 2006.
111. Normant E, Paez G and West KA: The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. *Oncogene* 30: 2581-2586, 2011.
112. Neckers L and Workman P: HSP90 molecular chaperone inhibitors: are we there yet? *Clin Cancer Res* 18: 64-76, 2012.
113. Modi S, Stopeck A and Linden H: HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. *Clin Cancer Res* 17: 5132-5139, 2011.
114. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. *Cell* 144: 646-674, 2011.
115. Khong T and Spencer A: Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. *Mol Cancer Ther* 10: 1909-1917, 2011.
116. Workman P, Burrows F, Neckers L and Rosen N: Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. *Ann NY Acad Sci* 1113: 202-216, 2007.
117. Hartl FU: Chaperone-assisted protein folding: the path to discovery from a personal perspective. *Nat Med* 17: 1206-1210, 2011.
118. Tiroli-Cepeda AO and Ramos CH: An overview of the role of molecular chaperones in protein homeostasis. *Protein Pept Lett* 18: 101-109, 2011.
119. Patel HJ, Modi S, Chiosis G and Taldone T: Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. *Expert Opin Drug Discov* 6: 559-587, 2011.
120. Sequist LV, Gettinger S and Natale R: A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. *J Clin Oncol* 27: 15s, 2009.
121. McCollum AK, Teneyck CJ, Sauer BM, Toft DO and Erlichman C: Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxy geldanamycin through a glutathione-mediated mechanism. *Cancer Res* 66: 10967-10975, 2006.
122. Didelot C, Lanneau D, Brunet M, Bouchot A, Cartier J, Jacquelin A, Ducoroy P, Cathelin S, Decolonne N, Chiosis G, Dubrez-Daloz L, Solary E and Garrido C: Interaction of heat-shock protein 90 beta isoform (HSP90 beta) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation. *Cell Death Differ* 15: 859-866, 2008.
123. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL and Jay DG: Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. *Nat Cell Biol* 6: 507-514, 2004.
124. Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, Tong M, Chang G and Luo Y: The regulatory mechanism of Hsp90 alpha secretion and its function in tumor malignancy. *Proc Natl Acad Sci USA* 106: 21288-21293, 2009.